Golden Meditech
48/F, Bank of China Tower
1 Garden Road, Central
HongKong
China
Website: http://www.goldenmeditech.com/
66 articles about Golden Meditech
-
Golden Meditech Announces FY2019/2020 Annual Results
6/30/2020
Sustainable Growth in Beijing Sunbow O&G Hospital, Interim Achievements in Cell Therapy Clinical Trials
-
Golden Meditech's Associate, Cellenkos, Focuses on the Development of Cell-theray for Treatment of COVID-19 Mediated Acute Respiratory Distress Syndrome (CoV-ARDS)
3/18/2020
Golden Meditech Holdings Limited, a leading integrated healthcare enterprise in China, announced that its associate, Cellenkos, Inc. has submitted a clinical development proposal to the Biomedical Advanced Research and Development Authority to start a Phase 1/2 clinical trial with CK0802 for treatment of COVID-19 mediated acute respiratory distress syndrome.
-
Golden Meditech Announces FY2018/2019 Annual Results
6/28/2019
Growth Achieved in Revenue and Business Diversification Synergies from Each Business Segment, Steady Expansion in New Biomedical Businesses
-
Five Directors of Golden Meditech Voluntarily Resigned Due to Personal Reasons
5/24/2019
New Members on Board, the Company's Major Shareholder Maintains Full Confidence in Future Business Development
-
Golden Meditech and HKBU Team Up to Conduct Cell Therapy Research
4/17/2019
Golden Meditech Holdings Limited, a leading integrated healthcare enterprise in China, announced that it has formed a collaboration with the Department of Biology of Hong Kong Baptist University to conduct in-depth research in the area of cell therapy, particularly treating neurodegenerative diseases with stem cells.
-
Golden Meditech Announces FY2018/2019 Interim Results
11/26/2018
Focusing on Business Diversification Strategies and Achieved Double-Digit Group Revenue Growth
-
Golden Meditech Announces FY2017/2018 Annual Results
6/27/2018
Healthcare Services Business Achieves Organic Growth and Diversification
-
Golden Meditech's Largest Shareholder Further Increased Shareholdings
3/19/2018
Golden Meditech Holdings Limited is pleased to announce that the Company's largest shareholder Mr. Kam Yuen, Chairman and Chief Executive Officer of the Group, has further increased his shareholding in Golden Meditech by acquiring a total of 9,300,000 shares through Bio Garden Inc.
-
Golden Meditech's Largest Shareholder Acquired Additional 9,068,000 Shares
3/14/2018
Golden Meditech Holdings Limited is pleased to announce that the Company's largest shareholder Mr. Kam Yuen, Chairman and Chief Executive Officer of the Group, has further increased his shareholding in Golden Meditech.
-
Golden Meditech's Subsidiary Completes Acquisition of 50% Equity Interest in ASA
2/28/2018
-
Golden Meditech Lays Out Strategic Plan across the Value Chain in the Emerging Biomedical Industry
2/26/2018
Licenses granted to provide genetic testing and cell a& tissue storage services in Shanghai, synergizing with existing immunotherapy investments, paving the way for precision medicine.
-
Golden Meditech Declares a Special Dividend to Shareholders
2/13/2018
Additionally, the Company is proactively looking for investment opportunities, if there are no suitable investment projects, the Board may consider declaring further special dividend.
-
Golden Meditech Announces FDA Registration of GMP Manufacturing Facility by its Associate, Cellenkos
2/7/2018
Golden Meditech announces that its associate, Cellenkos successfully registered its's stand-alone, manufacturing facility as good manufacturing practice compliant with FDA.
-
Golden Meditech Acquires 16.14% Interest of Ying Peng Hui Kang Fund
2/5/2018
Such investment in Ying Peng Hui Kang Fund may yield potential annual rate of return of 9%.
-
Golden Meditech Announces Close of Repurchase of TDR for the Delisting of TDR on TWSE
2/1/2018
The Company is obliged to repurchase approximately 49.21 million outstanding TDRs at a total consideration of approximately NT$219 million.
-
Golden Meditech Completes Sale of Equity Interest in China Cord Blood Corporation
1/31/2018
Golden Meditech is pleased to announce that the sale of 65.4% of the issued share capital of China Cord Blood Corporation to Nanjing Yingpeng Huikang Medical Industry Investment Partnership has been completed.
-
Golden Meditech Announces FY2017/2018 Interim Results
11/30/2017
Golden Meditech announces today its interim results for the six months ended 30 September 2017.
-
Golden Meditech and GE Healthcare Team Up to Develop Safe and Efficient Cord Blood Storage Services
11/16/2017
Pursuant to the collaboration, GE Healthcare will provide an integrated and automated digital system and solutions to the Group's umbilical cord blood cryopreservation processes, aiming to provide efficient storage services to customers at large.
-
Golden Meditech Announces the Proposed Voluntary Delisting of TDR on TWSE
10/30/2017
Golden Meditech today announces that the board of directors of the Company resolved to initiate an application for the voluntary delisting of the TDR from the TWSE, the repurchase of TDR resulting from the Voluntary Delisting and the TDR conversion offer.
-
Golden Meditech Announces FY2016/2017 Annual Results
6/28/2017